• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 - 2025
• Five Forces Analysis
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Type
o Market segments
o Comparison by Type
o Depression drugs - Market size and forecast 2020-2025
o Multiple sclerosis drugs - Market size and forecast 2020-2025
o Schizophrenia drugs - Market size and forecast 2020-2025
o Bipolar disorder therapeutics - Market size and forecast 2020-2025
o Epilepsy drugs - Market size and forecast 2020-2025
o Others - Market size and forecast 2020-2025
o Market opportunity by Type
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o Europe - Market size and forecast 2020-2025
o North America - Market size and forecast 2020-2025
o Asia - Market size and forecast 2020-2025
o ROW - Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o AstraZeneca Plc
o Boehringer Ingelheim International GmbH
o Eli Lilly and Co.
o GlaxoSmithKline Plc
o Johnson and Johnson Inc.
o Merck and Co. Inc.
o Novartis AG
o Otsuka Holdings Co. Ltd.
o Pfizer Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2020 - 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 - 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2020
• 21: Type - Market share 2020-2025 (%)
• 22: Comparison by Type
• 23: Depression drugs - Market size and forecast 2020-2025 ($ million)
• 24: Depression drugs - Year-over-year growth 2020-2025 (%)
• 25: Multiple sclerosis drugs - Market size and forecast 2020-2025 ($ million)
• 26: Multiple sclerosis drugs - Year-over-year growth 2020-2025 (%)
• 27: Schizophrenia drugs - Market size and forecast 2020-2025 ($ million)
• 28: Schizophrenia drugs - Year-over-year growth 2020-2025 (%)
• 29: Bipolar disorder therapeutics - Market size and forecast 2020-2025 ($ million)
• 30: Bipolar disorder therapeutics - Year-over-year growth 2020-2025 (%)
• 31: Epilepsy drugs - Market size and forecast 2020-2025 ($ million)
• 32: Epilepsy drugs - Year-over-year growth 2020-2025 (%)
• 33: Others - Market size and forecast 2020-2025 ($ million)
• 34: Others - Year-over-year growth 2020-2025 (%)
• 35: Market opportunity by Type
• 36: Customer landscape
• 37: Market share by geography 2020-2025 (%)
• 38: Geographic comparison
• 39: Europe - Market size and forecast 2020-2025 ($ million)
• 40: Europe - Year-over-year growth 2020-2025 (%)
• 41: North America - Market size and forecast 2020-2025 ($ million)
• 42: North America - Year-over-year growth 2020-2025 (%)
• 43: Asia - Market size and forecast 2020-2025 ($ million)
• 44: Asia - Year-over-year growth 2020-2025 (%)
• 45: ROW - Market size and forecast 2020-2025 ($ million)
• 46: ROW - Year-over-year growth 2020-2025 (%)
• 47: Key leading countries
• 48: Market opportunity by geography ($ million)
• 49: Impact of drivers and challenges
• 50: Vendor landscape
• 51: Landscape disruption
• 52: Industry risks
• 53: Vendors covered
• 54: Market positioning of vendors
• 55: AstraZeneca Plc - Overview
• 56: AstraZeneca Plc - Product and service
• 57: AstraZeneca Plc - Key offerings
• 58: AstraZeneca Plc - Key customers
• 59: AstraZeneca Plc - Segment focus
• 60: Boehringer Ingelheim International GmbH - Overview
• 61: Boehringer Ingelheim International GmbH - Business segments
• 62: Boehringer Ingelheim International GmbH - Key offerings
• 63: Boehringer Ingelheim International GmbH - Key customers
• 64: Boehringer Ingelheim International GmbH - Segment focus
• 65: Eli Lilly and Co. - Overview
• 66: Eli Lilly and Co. - Business segments
• 67: Eli Lilly and Co. - Key offerings
• 68: Eli Lilly and Co. - Key customers
• 69: Eli Lilly and Co. - Segment focus
• 70: F. Hoffmann-La Roche Ltd. - Overview
• 71: F. Hoffmann-La Roche Ltd. - Business segments
• 72: F. Hoffmann-La Roche Ltd. - Key offerings
• 73: F. Hoffmann-La Roche Ltd. - Key customers
• 74: F. Hoffmann-La Roche Ltd. - Segment focus
• 75: GlaxoSmithKline Plc - Overview
• 76: GlaxoSmithKline Plc - Business segments
• 77: GlaxoSmithKline Plc - Key offerings
• 78: GlaxoSmithKline Plc - Key customers
• 79: GlaxoSmithKline Plc - Segment focus
• 80: Johnson and Johnson Inc. - Overview
• 81: Johnson and Johnson Inc. - Business segments
• 82: Johnson and Johnson Inc. - Key offerings
• 83: Johnson and Johnson Inc. - Key customers
• 84: Johnson and Johnson Inc. - Segment focus
• 85: Merck and Co. Inc. - Overview
• 86: Merck and Co. Inc. - Business segments
• 87: Merck and Co. Inc. - Key offerings
• 88: Merck and Co. Inc. - Key customers
• 89: Merck and Co. Inc. - Segment focus
• 90: Novartis AG - Overview
• 91: Novartis AG - Business segments
• 92: Novartis AG - Key offerings
• 93: Novartis AG - Key customers
• 94: Novartis AG - Segment focus
• 95: Otsuka Holdings Co. Ltd. - Overview
• 96: Otsuka Holdings Co. Ltd. - Business segments
• 97: Otsuka Holdings Co. Ltd. - Key offerings
• 98: Otsuka Holdings Co. Ltd. - Key customers
• 99: Otsuka Holdings Co. Ltd. - Segment focus
• 100: Pfizer Inc. - Overview
• 101: Pfizer Inc. - Business segments
• 102: Pfizer Inc. - Key offerings
• 103: Pfizer Inc. - Key customers
• 104: Pfizer Inc. - Segment focus
• 105: Currency conversion rates for US$
• 106: Research Methodology
• 107: Validation techniques employed for market sizing
• 108: Information sources
• 109: List of abbreviations

Companies Mentioned
. AstraZeneca Plc
. Boehringer Ingelheim International GmbH
. Eli Lilly and Co.
. F. Hoffmann-La Roche Ltd.
. GlaxoSmithKline Plc
. Johnson and Johnson Inc.
. Merck and Co. Inc.
. Novartis AG
. Otsuka Holdings Co. Ltd.
. Pfizer Inc.